Click here for slides on this topic


Rosuvastatin

A drug in the statin (HMG-CoA reductase inhibitor) class that is indicated to treat high cholesterol as an adjunct to diet, and to reduce cardiovascular disease.
The following content matched the glossary term: Rosuvastatin

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Risk of incident diabetes among patients treated with statins: population based study

Top

Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610 doi:10.1136/bmj.f2610.

Clinical Insights in Diabetes Newsletter November 2012

Top

Clinical Insights® in Diabetes Newsletter November 2012.

Statins and diabetes, Roux-en-Y for type 2 diabetes and obesity, sitagliptin or liraglutide for type 2 diabetes treatment, obesity and mortality, and DPP-4 inhibitors and cardiovascular disease.

NDEI.org Press Release Peter Libby, MD, on New JUPITER Analysis: “These Data Put Diabetes Risk from Statin Therapy in Perspective”

Top

Peter Libby, MD, on New JUPITER Analysis: "These Data Put Diabetes Risk from Statin Therapy in Perspective" NDEI.org expert commentary explores statins and diabetes risk September 18, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®) published expert commentary from Peter Libby, MD, on a new analysis of the landmark JUPITER primary prevention trial demonstrating that the cardiovascular and mortality benefits conferred by statin therapy outweigh the risk for developing diabetes among patients at low risk for cardiovascular disease (CVD).

Statins and new-onset diabetes: a retrospective longitudinal cohort study

Top

Ma T, Tien L, Fang CL, Liou YS, Jong GP. Statins and new onset diabetes a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977-1983. Statins have been linked to new-onset diabetes (NOD); however, the effect of statins on the development of NOD in patients with hypertension and dyslipidemia has not been well studied.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Top

Sattar N, Preiss D, Murrary HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. Sattar and colleagues conducted a meta-analysis to assess whether a relationship between statin use and development of diabetes exists.

NDEI.org Expert Commentary on the JUPITER trial Peter Libby

Top

Peter Libby, MD, provides expert commentary on a new analysis from the JUPITER trial examining whether the benefits of statin use outweigh diabetes risk in primary prevention low-risk patients

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein

Top

Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. The Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, double-blind, placebo-controlled trial which sought to examine whether rosuvastatin treatment compared with placebo would decrease the rate of first cardiovascular (CV) events.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

1 2 Next 

Slide Library Results

Search Results for: Rosuvastatin Slides Found: 47
JUPITER: Design
JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?
JUPITER Analysis: Design
JUPITER Analysis: Baseline Characteristics 0 or ≥1 Major Diabetes Risk Factor*
JUPITER Analysis: Increased Diabetes Risk With ≥1 Risk Factor* at Baseline
JUPITER Analysis: Incident Diabetes by Treatment Group
JUPITER Analysis: Average Time to Diabetes Diagnosis
JUPITER Analysis: Risk Reduction With Rosuvastatin ≥1 Major Diabetes Risk Factor*
JUPITER Analysis: Risk Reduction With Rosuvastatin No Major Diabetes Risk Factor*
JUPITER Analysis: CV Risk Reduction Among Subjects Who Developed Diabetes
JUPITER Analysis: Conclusions
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
JUPITER: Study Design
JUPITER: Lipid and HsCRP Levels
JUPITER Results: Primary Endpoint
JUPITER Results: Components of Primary Endpoint
JUPITER Results: Summary
JUPITER Analysis: Limitations
FIN-D2D: Association Between Statin Use and Diabetes Incidence Design
FIN-D2D: Statin Use at Baseline and Diabetes Incidence At 1 Year
FIN-D2D: Statin Use at Baseline and Glucose Values at 1 Year
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin Over 14 Years
Incident Diabetes Rate Greater with High- Vs Moderate- or Low-Potency Statins
Statins and Diabetes, Cancer: Meta-Analysis
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin for Primary and Secondary Prevention
Incident Diabetes by Statin Use: Design
ACC/AHA Cholesterol Guidelines 2013: High- and Moderate-Intensity Statin Therapy
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
Statin Adherence Associated With Increased Type 2 Diabetes Risk | NDEI
Statin Adherence & Type 2 Diabetes Risk | NDEI
Statin Adherence & Risk for New-Onset Type 2 Diabetes | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
JUPITER Secondary Analysis Assesses Statin Use & Diabetes Risk | NDEI
JUPITER High-Intensity Rosuvastatin & Lipoprotein Particles | NDEI
JUPITER Effect of High-Intensity Rosuvastatin on Lipoproteins Diabetes | NDEI
JUPITER Rosuvastatin & Incident Type 2 Diabetes | NDEI
JUPITER Insulin Resistance Associated With Risk Factors | NDEI
JUPITER Incident Diabetes Associated With More Risk Factors Rosuvastatin | NDEI
HOPE-3 Primary Prevention for Individuals at Intermediate CV Risk
HOPE-3 CV Event Reduction With Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 LDL & Lipoprotein Reductions With Rosuvastatin Vs Placebo | NDEI
HOPE-3 Safety of Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 Incidence Diabetes With Rosuvatatin Vs Placebo PPT | NDEI
HOPE-3 Lipid- & BP-Lowering Therapy for Primary Prevention PPT | NDEI
HOPE-3 Lipid- & BP-Lowering Intermediate Risk CV Events PPT | NDEI